May 10, 2022

54gene Founder and CEO, Dr. Abasi Ene-Obong, said, “Along with our partners, we are proud to be leading the new frontier of African genomics. Precision medicine goes against the one-size-fits-all approach to disease treatment as it is more inclusive, with people treated on their unique genetic makeup. With more than 200 ethnic groups and 500 different languages, Nigeria has one of the most diverse ethnolinguistic concentrations in the world. This pioneering study from the Nigerian population provides an excellent window into the representation of diversity across Africa. With recruitment nearly complete and the commencement of data generation and bioinformatics analysis, we are excited at how this study makes the promise of precision medicine more attainable to Nigerians, Africans and the global population.” Through 54gene’s ACTG, the consortium operates as a unique public-private partnership involving leading African scientists guided by a team of global genomic leaders as the Scientific Advisory Board to achieve the mission of the ACTG. The consortium, which is made up of scientists from 54gene, the Nigerian Institute of Medical Research, and the Center for Genomics Research and Innovation at the National Biotechnology Development Agency as well as researchers from multiple academic institutions in Nigeria and London School of Hygiene and Tropical Medicine, is built on a shared vision of positioning African populations to benefit from advances in genomic science. According to the paper, as of January 2019, approximately 3% of genomic data being used for genome wide association studies (GWAS) came from people of African descent, with this statistic dropping to 1.1% in 2021. The paper details efforts in building an important resource that could significantly enable African populations to benefit from the global efforts at achieving precision medicine for various diseases. The study spans the breadth of the Nigerian population with data gathered from the 6 geopolitical zones in the country and sampling from the majority of the more than200 ethnolinguistic groups, with ethically consulted participants being recruited falling under two categories: disease cases recruited from disease specialist clinics, and community cases which are individuals with initially unknown diseases recruited from communities through household surveys. Aminu Yakubu, VP Research Governance and Ethics, said, “Building on the legacy of the H3Africa project, the capacity building objective of the NCD-GHS in the 100K Genome Project is a strategic undertaking that would catalyse the future we envisage – of Africans with the skillset and knowledge, able to lead genomic insights generation and development to address health challenges faced by Africans over the long haul. It is a people-facing impact creation initiative that puts the social value of the work we do at the center, facilitated through the African Center for Translational Genetics . ”  The focus of one of the NCD-GHS agendas on governance and ethics was deliberate to ensure that we are aligned with existing country-specific and international best practices. Our commitment to also support academic thought leadership on ethics and governance issues in genomics research would allow us to evolve as we learn of better ways to protect the welfare of research participants and ensure fairness in research collaborations.”  added Yakubu. Readers109